quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:05:46·1710d
PRRelease
AzurRx BioPharma, Inc. logo

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

AZRX· AzurRx BioPharma, Inc.
Health Care
Original source

Companies

  • AZRX
    AzurRx BioPharma, Inc.
    Health Care

Recent analyst ratings

  • Aug 2UpdateHC Wainwright & Co.$2.00

Related

  • SEC1668d
    AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events
  • SEC1675d
    AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR1675d
    AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
  • SEC1682d
    AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR1683d
    AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
  • INSIDER1683d
    SEC Form 4 filed by Coelho Mary Theresa
  • SEC1684d
    AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR1684d
    AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022